The May 26th 2014 issue of Chemical&Engineering News reported on a promising drug with a future to be determined by the courts.
Cancer researcher Wafik S. El-Deiry of Pennsylvania State University and Penn State Milton S. Hershey Medical Center and colleagues found TIC10 in a search of a free National Cancer Institute database and pinpointed its anticancer activity.
They found that the compound stimulates gene expression of a tumor suppressor protein called TRAIL. TIC10 stands for TRAIL-inducing compound 10.
The Penn State group patented the compound with the top structure:
See U.S. 8673923.